BRCA-P: An International Randomised Phase III Study Evaluating The RANK Ligand Inhibitor Denosumab For The Prevention Of Breast Cancer In BRCA1 Mutation Carriers
Funder
National Health and Medical Research Council
Funding Amount
$2,589,049.00
Summary
Women with a faulty BRCA1 gene are at high lifetime risk for breast cancer. Identifying a safe and effective prevention therapy is therefore a ‘holy grail’. We have discovered that denosumab, used to treat osteoporosis or breast cancer spread to bone, could be ‘repurposed’ as a prevention drug. BRCA-P is an international randomised controlled study that will determine if denosumab prevents breast cancer. Associated translational research will facilitate swift transfer to the clinic.
Clinicopathological Characterisation Of Male Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$113,322.00
Summary
Male Breast Cancer is an uncommon and poorly understood disease. Due to its low frequency, there is a paucity of studies with large numbers of patients. Our aim will be to establish one of the largest worldwide databases of Male Breast Cancer. This will allow us to more thoroughly investigate clinical, pathological and molecular characteristics of male breast cancer, improve treatment of these patients and potentially develop novel and innovative strategies for treatment of female breast cancer.
A Systems Biology Approach To Defining Therapeutic Targets In Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$633,112.00
Summary
Breast cancer is a very complex disease affecting large numbers of women. Current treatment strategies are effective at controlling the disease for patients, however many continue to be burdened by their disease as their tumour either does not respond or develops resistance to the treatment. We will use mathematical approaches to analyse large and complex data sets generated from breast cancers to identify new therapeutic targets and improve patient outcomes.